This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.
The site in the US will produce CAR T-cell therapies for patients with blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.
CAR-T therapies including Kymriah (tisagenlecleucel). ... Adapatimmune is also involved in CAR-T and early in 2020 signed a deal with Astellas on both CAR-T and TCR allogeneic therapies.
The European Commission (EC) has approved Bristol Myers Squibb/bluebird bio’s first-in-class anti-B-cell maturation antigen (BCMA) CAR T cell therapy Abecma (idecabtagene vicleucel) for patients with ... Abecma is the first CAR T cell therapy that is
The combined strength of Kite’s leadership in CAR T-cell therapies and our cutting-edge iPSC platform will potentially accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities ... Xanthopoulos, co-founder, chairman and chief
The CAR-T therapy also met key secondary endpoints of complete response rate and progression-free survival compared to standard of care, BMS said in a statement. ... These positive interim results build on our commitment to bring CAR-T cell therapies
Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell therapies have shown transformational potential for the treatment of haematologic malignancies and we, with our
More from news
Approximately 3 fully matching, plus 93 partially matching documents found.
more as many of the parts don’t mesh together, are fitted at different times and operate across a crowded spectrum. ... We will see faster progress in areas such as CAR-T and gene therapies because these are personalised medicines and the patient is
Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers
impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.
It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer
For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...